Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In this podcast episode, listen to Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, PhD, discuss new data and studies in MDS and MPNs presented at ASH 2020.
Amy E. DeZern, MD, MHS
Srdan Verstovsek, MD, PhD
Released: February 5, 2021

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:

  • 3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 study
  • A post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients
  • 5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV study
  • Phase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependent
  • Analysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.

Presenters:

Amy E. DeZern, MD, MHS
Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Srdan Verstovsek, MD, PhD
Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Virtual presentation by Shannon N. Westin, MD, MPH, on improving health equity for patients with endometrial cancer, from Clinical Care Options (CCO)

Shannon N. Westin, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 24, 2021 Expired: September 23, 2022

Phase I data on mesothelin-targeted CAR T-cell therapy with or without pembrolizumab in malignant pleural cancers, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 24, 2021

From Clinical Care Options (CCO), a video webinar on fundamentals of CAR T-cell therapy for pharmacy and managed care professionals

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 24, 2021 Expired: September 23, 2022

Clinical Care Options (CCO) commentary in which Dr. Daniel Pollyea provides his strategies for treating patients with myelodysplastic syndrome (MDS)

Daniel Pollyea, MD, MS Released: September 24, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue